We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
  • AstraZeneca transfers rights for Eklira and Duaklir to Covis Pharma EuropeanPharmaceuticalReview
    November 05, 2021
    AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma.
  • Circassia pulls plug on AZ agreement pharmatimes
    April 10, 2020
PharmaSources Customer Service